Spexis and SPRIM Global Investments (SGI) announce plans for clinical trial partnership to fund up to half of the projected Phase 3 clinical development costs of ColiFin®
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
